By Julie Steenhuysen CHICAGO (Reuters) – The United States may not need AstraZeneca’s (NASDAQ 🙂 COVID-19 vaccine, even if it gets US regulatory approval, Anthony Fauci, the chief infectious disease physician at the United States, told Reuters. country. The vaccine, once hailed as another milestone in the fight against the COVID-19 pandemic, has been haunted by questions since late last year, even as its use has been licensed by dozens of countries, not including the United States. Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to the White House, said the United States has enough contracts with other vaccine manufacturers to vaccinate its entire population, and possibly enough for booster shots in the fall. When asked if the United States will use the AstraZeneca vaccine doses, he said: “That is still up in the air. My general opinion is that, given the contractual relationships we have with various companies, we have enough vaccine to meet all the requirements. “. our needs without invoking AstraZeneca. “Late last year, the drugmaker and the University of Oxford published data from a previous trial with two different efficacy readings as a result of a dosing error. Then, in March, more than A dozen countries temporarily suspended use of the AstraZeneca vaccine after reports linked it to a rare blood clotting disorder. Also in March, a US health agency said data from the company gave an incomplete picture of its efficacy. Days later, AstraZeneca published results that showed decreased efficacy, albeit still strong. Fauci said that “if you look at the number (of doses) that we are going to receive, the amount you can get from J&J (NYSE 🙂 by Novavax (NASDAQ 🙂 by Moderna (NASDAQ 🙂 if I contract for more, we can probably handle whatever boost we need, but I can’t say for sure. ”
Disclaimer: Fusion Media wishes to remind you that the data contained on this website is not necessarily accurate or in real time. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so the prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur as a result of the use of this data. Fusion Media or anyone involved with Fusion Media will accept no responsibility for loss or damage as a result of reliance on information, including data, quotes, charts, and buy / sell signals contained on this website. Be fully informed about the risks and costs associated with trading the financial markets, it is one of the riskiest forms of investment possible.